Morgan Stanley (NYSE:MS) initiated coverage on shares of GlaxoSmithKline (NYSE:GSK:LN) (NYSE: GSK), a $72.5 billion pharmaceutical giant with a 25-year track record of consistent dividend payments, ...

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

Sentiment plummeted to a seven-month low as one-year inflation expectations surged to their highest point since late 2023. The US economy added 143,000 jobs in January, fewer than expected. The ...

Key Insights Significantly high institutional ownership implies GSK's stock price is sensitive to their trading ...

In a report released today, Emily Field from Barclays maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with a price target ...

SAN DIEGO, CA / ACCESS Newswire / February 10, 2025 / Robbins LLP reminds stockholders that a class action was filed on ...

You can also contact the Law Offices of Frank R. Cruz to discuss your legal rights by email at [email protected], by telephone at (310) 914-5007, or visit our website at www.frankcruzlaw.com .

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

Though the drug’s U.S. sales were adversely impacted due to favorable price impacts in the year-ago period, continued growth in ex-U.S. territories partially offset the same. GSK added £11 ...

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in. The content of this article is provided for information ...

The GSK share price rallied 6% this morning after the company published a surprisingly strong set of full-year results for 2024. Many metrics beat analysts’ expectations, including sales and revenue.